Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004.

Depp C, Ojeda VD, Mastin W, Un├╝tzer J, Gilmer TP.

Psychiatr Serv. 2008 Oct;59(10):1169-74. doi: 10.1176/appi.ps.59.10.1169.

PMID:
18832503
2.

Trends in Atypical Antipsychotics Prescribed to Children Six Years of Age or Less on Medicaid in Kentucky.

Lohr WD, Chowning RT, Stevenson MD, Williams PG.

J Child Adolesc Psychopharmacol. 2015 Jun;25(5):440-3. doi: 10.1089/cap.2014.0057. Epub 2015 Apr 21.

3.

Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.

Pillarella J, Higashi A, Alexander GC, Conti R.

Psychiatr Serv. 2012 Jan;63(1):83-6. doi: 10.1176/appi.ps.201100092.

4.

The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Matone M, Localio R, Huang YS, dosReis S, Feudtner C, Rubin D.

Health Serv Res. 2012 Oct;47(5):1836-60. doi: 10.1111/j.1475-6773.2012.01461.x. Epub 2012 Sep 4.

5.

Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China.

Xiang YT, Hu C, Wang G, Zheng QW, Fang YR, Ungvari GS, Kilbourne AM, Lai KY, Si TM, Chen DF, Lu Z, Yang HC, Hu J, Chen ZY, Huang Y, Sun J, Wang XP, Li HC, Zhang JB, Chiu HF.

Hum Psychopharmacol. 2012 Nov;27(6):626-31. doi: 10.1002/hup.2262. Epub 2012 Oct 2.

6.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
7.

Bipolar-I patient characteristics associated with differences in antimanic medication prescribing.

Busch AB, Frank RG, Sachs G, Normand SL.

Psychopharmacol Bull. 2009;42(1):35-49.

8.

Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.

Opolka JL, Rascati KL, Brown CM, Gibson PJ.

Psychiatr Serv. 2004 Feb;55(2):151-6.

PMID:
14762239
9.

Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study.

Murphy AL, Gardner DM, Cooke C, Kisely S, Hughes J, Kutcher SP.

BMC Psychiatry. 2013 Jul 27;13:198. doi: 10.1186/1471-244X-13-198.

10.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
11.

State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia.

Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT.

Psychiatr Serv. 2014 Jan 1;65(1):121-4. doi: 10.1176/appi.ps.201300001.

PMID:
24382765
12.

Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.

Kulkarni J, Filia S, Berk L, Filia K, Dodd S, de Castella A, Brnabic AJ, Lowry AJ, Kelin K, Montgomery W, Fitzgerald PB, Berk M.

BMC Psychiatry. 2012 Dec 17;12:228. doi: 10.1186/1471-244X-12-228.

13.

Prescribing of antipsychotics in UK primary care: a cohort study.

Marston L, Nazareth I, Petersen I, Walters K, Osborn DP.

BMJ Open. 2014 Dec 18;4(12):e006135. doi: 10.1136/bmjopen-2014-006135.

14.

Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.

Morrato EH, Campagna EJ, Brewer SE, Dickinson LM, Thomas DS, Miller BF, Dearing J, Druss BG, Lindrooth RC.

JAMA Psychiatry. 2016 Jul 1;73(7):721-30. doi: 10.1001/jamapsychiatry.2016.0538.

PMID:
27167755
15.

Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.

Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS.

Psychiatr Serv. 2013 Mar 1;64(3):223-9. doi: 10.1176/appi.ps.201200081.

PMID:
23242390
16.

Trends in the treatment of bipolar disorder by outpatient psychiatrists.

Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA.

Am J Psychiatry. 2002 Jun;159(6):1005-10.

PMID:
12042190
17.

Treatment of Young People With Antipsychotic Medications in the United States.

Olfson M, King M, Schoenbaum M.

JAMA Psychiatry. 2015 Sep;72(9):867-74. doi: 10.1001/jamapsychiatry.2015.0500.

PMID:
26132724
18.

Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.

Kilbourne AM, Post EP, Bauer MS, Zeber JE, Copeland LA, Good CB, Pincus HA.

J Affect Disord. 2007 Sep;102(1-3):145-51. Epub 2007 Feb 5.

PMID:
17276514
19.

Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program.

Li J, McCombs JS, Stimmel GL.

J Affect Disord. 2002 Sep;71(1-3):131-9.

PMID:
12167509
20.

Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents.

Chen H, Mehta S, Aparasu R, Patel A, Ochoa-Perez M.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):299-308. doi: 10.1002/pds.3568. Epub 2014 Jan 24.

PMID:
24459113

Supplemental Content

Support Center